NCT01240252View on ClinicalTrials.gov

Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Human insulin

U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER